REMAP-CAP TRIAL SAYS NO EVIDENCE OF HARM ASSOCIATED WITH THE ADMINISTRATION OF CONVALESCENT PLASMA IN COVID-19 PATIENTS
Remap-Cap Trial Says No Evidence Of Harm Associated With The Administration Of Convalescent Plasma In Covid-19 Patients
![Reuters logo](/images/reuters.jpg)
REMAP-CAP TRIAL SAYS NO EVIDENCE OF HARM ASSOCIATED WITH THE ADMINISTRATION OF CONVALESCENT PLASMA IN COVID-19 PATIENTS